↓ Skip to main content

Dove Medical Press

Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines

Overview of attention for article published in Drug Design, Development and Therapy, January 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
17 Mendeley
Title
Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines
Published in
Drug Design, Development and Therapy, January 2020
DOI 10.2147/dddt.s228610
Pubmed ID
Authors

Mahnaz Mohammadi Kian, Mahdieh Salemi, Mohammad Bahadoran, Atousa Haghi, Nasrin Dashti, Saeed Mohammadi, Shahrbano Rostami, Bahram Chahardouli, Davood Babakhani, Mohsen Nikbakht

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 18%
Unspecified 2 12%
Student > Bachelor 1 6%
Student > Master 1 6%
Professor > Associate Professor 1 6%
Other 1 6%
Unknown 8 47%
Readers by discipline Count As %
Unspecified 2 12%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Environmental Science 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Materials Science 1 6%
Other 0 0%
Unknown 11 65%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2024.
All research outputs
#20,031,563
of 25,483,400 outputs
Outputs from Drug Design, Development and Therapy
#1,313
of 2,271 outputs
Outputs of similar age
#340,984
of 476,322 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 43 outputs
Altmetric has tracked 25,483,400 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,271 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 476,322 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.